on VALBIOTIS (EPA:ALVAL)
Valbiotis approves share buyback program at General Meeting
On November 5, 2024, Valbiotis, a French laboratory specializing in food supplements for metabolic and cardiovascular disorders, held its Ordinary General Meeting in La Rochelle. The event, chaired by Sébastien Peltier, saw shareholders unanimously approve two resolutions. One of them authorizes the Management Board to buy back shares of the company, within the framework of a liquidity contract, limited to 1% of the share capital.
This buyback program aims to stabilize the share price on the market. Valbiotis continues to focus on its research and development activities, while supporting value for its shareholders. The documents relating to this meeting are available on the company's website.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all VALBIOTIS news